Improvement of Depression With Use of ATP
This clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. Participants will be patients with moderate to severe depression who meet the inclusion criteria during the screening period. After recruitment written informed consent form will be signed and the baseline evaluation will be done then the treatment period follows. The subjects will be randomly assigned to a control group (escitalopram plus NA) and an ATP group (escitalopram plus adenosine disodium triphosphate(ATP)) in a 1:1 ratio for treatment, with a total number of 120 recruited patients. Assessment will be carried out as an analysis of changes in Hamilton Depression Rating Scale, cognitive function test, brain functional network, inflammatory markers, and other indicators in the first, second, and fourth week of intervention which will evaluate the effectiveness of ATP in improving moderate to severe depression preliminarily.
- EligibilityCriteria: Inclusion Criteria:  Meet DSM-V diagnostic criteria for moderate to severe depression. HAMD-24 scores ≥ 20. 18-65 female or male. Subjects who have not used any antipsychotic drugs, antidepressants, mood stabilizers (sodium valproate, lithium carbonate) or escitalopram treatment within the first month prior to the start of this study. Individuals without contraindications to SSRI. Individuals without contraindications to ATP. Written informed consent.  Exclusion Criteria:  Conduct clinical interviews using the Chinese version of the Mini International Neuropsychiatric Interview (MINI) to evaluate participants with various mental disorders other than depression (such as bipolar disorder, schizophrenia, personality split, etc.). Individuals with neurological disorders such as dementia. Individuals with a high risk of suicide. Pregnant and lactating women. Individuals with substance use disorder within one year prior to the start of this study. Contraindications to MRI. Physician evaluation was not suitable for participants in this study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult